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Anti-U is a rare red blood cell alloantibody that has been found exclusively in blacks. It can cause hemolytic disease
of the newborn and hemolytic transfusion reactions.
We describe the case of a female newborn presenting a strongly positive direct antiglobulin test due to an IgG antibody
in cord blood. Anti-U was recovered from cord blood using acid eluate technique. Her mother presented positive screening
of antibodies with anti-U identified at delivery. It was of IgG1 and IgG3 subclasses and showed a titer of 32. Monocyte
monolayer assay showed moderate interaction of Fc receptors with maternal serum with a positive result (3.1%). The
newborn was treated only with 48 hours of phototherapy for mild hemolytic disease. She recovered well and was discharged
on the 4th day of life.
We conclude that whenever an antibody against a high frequency erythrocyte antigen is identified in brown and black
pregnant women, anti-U must be investigated.
DESCRIPTORS: Anti-U. Antibody titration. Hemolytic disease of the newborn. Alloantibodies. Direct antiglobulin
test. Monocyte monolayer assay.
Anti-U was first reported by Wiener
et al.1 in 1953. It was found in a black
patient who had a fatal hemolytic
transfusion reaction. The authors also
reported the high frequency of U anti-
gen on red cells ; it was of near uni-
versal occurrence.
U antigen is part of the MNS blood
group system. This complex system of
over 40 antigens is carried on 2
glycophorins molecules or hybrid
molecules of the 2 proteins. Regard-
ing transfusion medicine, M, N, S, s,
and U antigens are the most important
ones. The M and N antigens are lo-
cated on glycophorin A (GPA), and S,
s, and U antigens are on glycophorin
B (GPB), encoded by GYPA and GYPB
genes respectively. The GYPA and
GYPB are members of the glycophorin
gene family encompassing a 330-kb
genomic segment located, in a very
close proximity, on chromosome 4,
band q312. The GYPA gene consists of
7 exons and has 97% sequence homol-
ogy with GYPB, which has 5 exons.
Glycophorins A (GPA) and B (GPB)
are major sialoglycoproteins of the
human erythrocyte membrane that bear
the antigenic determinants for the MN
and Ss blood groups. In addition to
the M or N and S or s antigens that
commonly occur in all populations,
about 40 related variant phenotypes
have been identified. These variants
include all the variants of the
Miltenberger complex and several
isoforms of Sta, and also, Dantu, Sat,
He, Mg, and deletion variants Ena, S-
s-U-, and Mk. Most of the variants are
resulted from gene recombinations be-
tween GYPA and GYPB3.
The high-incidence U antigen is a
labile structure, located near the cell
surface and is resistant to proteases4. U
antigen appears to be well developed
at birth. Marsh et al.5 reported U anti-
gen on neutrophils through adsorption
studies.
Less than 1% of blacks are U-nega-
tive and capable of producing
alloanti-U. In a study in 2,462 Brazil-
ian blood donors, all whites and
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browns were U-positive, and only
0.87% of blacks were U-negative. All
of U-negative blood donors were also
S-negative and s-negative simultane-
ously6.
Anti-U are generally non-comple-
ment binding IgG antibodies7 contain-
ing an IgG 1 component8, are uncom-
mon but are a recognized cause of
hemolytic disease of the fetus and new-
born (HDN).
There are 16 reports of HDN due to
anti-U including 1 resulting in still-
birth, all of them in black pregnant
women.
In this study, we present the first
case of HDN caused by anti-U identi-
fied in a brown woman.
CASE REPORT
A female newborn delivered at 38
and 2/7 weeks, weighing 2,960 g,
Apgar score 9/9, presented a strongly
positive direct antiglobulin test with
evidence of clinically significant mild
hemolysis. Anti-U was recovered from
an acid eluate of cord blood. Anti-UPR
was identified as subspecificity due to
its resistance to papain-treatment. The
baby´s red blood cells phenotyped as
M+N+S-s+U+He-. The mother, a brown
female, 36 years old, presented posi-
tive screening of antibodies (Indirect
Coombs test) at delivery. An anti-U re-
acting at antiglobulin phase was iden-
tified. The antibody was of IgG1 and
IgG3 subclasses and showed a titer of
32 by antiglobulin test. The red blood
cells phenotyped as M+N-S-s-U-He-.
Unfortunately it was not possible to
obtain prenatal data of this pregnancy.
She had had 4 earlier pregnancies. In
the last pregnancy, 3 years ago, no ir-
regular antibodies were detected in the
serum. A monocyte monolayer assay9
was devised to attempt to forecast in
vivo red cells survival from in vitro test.
The monocyte monolayer assay
showed moderate interaction of Fc
receptors with maternal serum, with a
positive result of 3.1%. Thirty-five
hours after birth, bilirubin was 6.9 mg/
dL, reticulocytes 2.4%, hemoglobin
12.1 g/dL, and hematocrit was 33.9%.
The newborn was only treated with
phototherapy for about 48 hours, re-
covered well and was discharged on
the 4th day of life.
DISCUSSION
HDN was a significant cause of fe-
tal mortality and morbidity until the
introduction of amniocentesis, intrau-
terine transfusion, controlled early de-
livery, and exchange transfusion in the
management of severely alloimmu-
nized women and their fetuses10. Typi-
cally, the serological diagnosis of HDN
includes a positive direct antiglobulin
test on the infant’s red blood cells and
the presence of an IgG red cell allo-
antibody in both maternal and cord
sera.
The severity of HDN can be as-
sessed with certainty only by measure-
ment of fetal parameters. However,
these invasive procedures may be risky
for the fetus. Initially, immuno-
hematological tests are performed on
maternal serum to identify antibodies
with a potential risk of HDN.
Although anti-D is the most com-
mon cause of hemolytic disease of
newborn, it should be remembered that
antibodies against other red blood cell
antigens, such as S, s, K, Fya, Fyb, Jka,
Jkb can cause severe and even fatal
HDN 7.
Antibody concentration is inferred
by indirect antiglobulin technique ti-
tration, or where possible, is quanti-
fied11. Titration is the most common
method used in a routine laboratory to
estimate the strength of an antibody.
Smith et al.12 recommended that an
anti-U titer of ≥128 or more at ≥17
weeks of gestation is an indication for
assessment of hemolysis in the fetus.
However, the authors found anti-U titer
of 4,000 in a pregnant woman at 38
weeks with no evidence of HDN. They
hypothesized that the destruction of
the antibody-coated red cells directed
against the fetal mononuclear phago-
cytes could be inhibited by HLA-de-
rived maternal alloantibodies13.
In the literature there are reports of
16 pregnancies complicated by anti-U,
all of them in black-origin individu-
als. The severity of HDN varied from
asymptomatic to fatal. The first case of
HDN due anti-U was related by
Alfonso and de Alvarez in 196114 with
no evidence of clinically significant
hemolysis. Seven other cases pre-
sented no clinical signs of HDN (1 re-
lated by Tuck & Studd15, 2 by Dopp &
Isham16, and 4 cases by Smith et al.12).
Smith et al.12 reported a newborn
with anti-U, who needed a simple red
blood cell transfusion. In 3 instances,
exchange transfusion was performed to
manage HDN to anti-U17,18,19.
Gottschall20 presented a case in
which exchange transfusion was per-
formed, but anti-D was also present,
and the contribution of the anti-U to
the hemolysis was therefore uncertain.
There was 1 report of intrauterine
death due to anti-U in 196421. Intrau-
terine transfusion procedure was per-
formed 3 times in 1 fetus, in which the
anti-U titer was 1,000 at 20 weeks of
gestation and arose to 16,000 at 32
weeks of gestation when a cesarean
section was needed. During the first
day of life, the newborn was given a
platelet transfusion and 2 exchange
transfusions. After that the baby was
transfused 3 times in the neonatal pe-
riod12.
A severe HDN caused by anti-U
was diagnosed retrospectively, when a
3-week-old black infant presented se-
vere hemolytic anemia and anti-U was
identified in his mother serum22.
Smith et al.12 recommended that an
anti-U titer of ≥128 or more at ≥17
weeks of gestation is an indication for
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assessment of hemolysis in the fetus.
Unfortunately, it was not possible
for us to assess prenatal laboratory
tests of the patient we reported. We
performed a monocyte monolayer as-
say (MMA) to forecast the severity of
HDN. This method, as well as other in
vitro cellular assays, is recognized to
have a good correlation in predicting
disease severity, although a high MMA
activity does not always indicate a se-
vere HDN23,24. In this report, the weak
positive result at MMA (3.1%) is in
accordance with the anti-U titer ob-
served in the maternal serum (32) and
with mild signs of HDN.
The mother´s red blood cell MNS
phenotyping showed a very rare pat-
tern (M+N-S-s-U-). In order to explain
this phenotyping result, or the
mother´s RBCs could lack GPB, or the
GPB could be hybrid25. Consequently,
this patient can produce other antibod-
ies against any antigen carried on
GPB.
Despite the fact that in this report
the HDN was of mild type, it is note-
worthy that, as far as we know, this is
the first report of HDN due to anti-U
identified in a brown woman. This
finding is particularly relevant in
countries like Brazil, where there is a
high miscegenation population rate,
and the brown group is one of the
most prevalent26.
In conclusion, based on the knowl-
edge that anti-U should be suspected
whenever an antibody to high fre-
quency antigen is detected in a serum
of previously pregnant or transfused
black individuals27, we suggest that
this recommendation be extended for
the brown group.
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hemolítica do recém-nascido devi-
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Méd. S. Paulo 58(6):320-323,
2003.
Anti-U é um aloanticorpo eritro-
citário raro detectado exclusivamente
em negros, que pode causar doença
hemolítica do recém-nascido e reações
transfusionais hemolíticas.
Relatamos o caso de um recém-
nascido, de sexo feminino, que apre-
sentou teste de antiglobulina direto
fortemente positivo, dirigido a um
anticorpo IgG em sangue de cordão
umbilical. Anti-U foi identificado por
técnica de eluição ácida. A mãe apre-
sentava pesquisa de anticorpos irregu-
lares positiva com anticorpo anti-U, de
subclasses IgG1 e IgG3, título 32, iden-
tificado ao nascimento. O ensaio de
monocamada de monócitos apresentou
resultado positivo (3.1%), mostrando
uma interação moderada de receptores
Fc com soro materno. O recém-nasci-
do foi tratado somente por fototerapia
durante 48 horas para uma doença
hemolítica leve. A criança recuperou-
se bem e teve alta médica no quarto
dia de vida.
Concluímos que quando um anti-
corpo contra um antígeno eritrocitário
de alta freqüência for identificado em
gestantes negras e pardas, anti-U deve
ser investigado.
DESCRITORES: Anti-U. Titulação
de anticorpo. Doença hemolítica do
recém-nascido. Aloanticorpos. Teste
de antiglobulina direto. Ensaio de
monocamada de monócitos.
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